

ersonal use only

MICRO-X

FINANCIAL RESULTS & OPERATIONAL UPDATE

Financial Year ended 30 June 2025

Kingsley Hall
Chief Executive Officer

28 August 2025



IMPORTANT NOTICE

MICRO-X

SCOPE & LIMITATIONS

This Presentation has been prepared by Micro-X Limited (**Micro-X** or the **Company**) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company's assets and liabilities, financial position and performance, profits and losses and prospects. This material in this Presentation may be supplemented with an oral presentation and/or other more detailed documents and should not be taken out of context. Although the information contained herein is based upon generally available information and has been obtained from third-party sources believed to be reliable, the Company does not guarantee its accuracy, and such information may be incomplete or condensed. The Company also refers to its filings made with the ASX Limited and the Australian Securities & Investments Commission.

FORWARD LOOKING INFORMATION

This Presentation contains forward looking and other subjective information. Such expectations, estimates, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties. Actual results and developments will almost certainly differ from those expressed or implied and recipients of this Presentation should make their own assessment of the expectations, estimates, projections and the relevant assumptions and calculations upon which the opinions, estimates and projections are based. No representation or warranty, express or implied, is given as to the accuracy or completeness of the information or opinions contained in this Presentation and no liability whatsoever is accepted by the Company, or its directors, members, officers, employees, agents or advisers for any use or, or reliance placed upon, such information or opinions.

NOT AN OFFER FOR SECURITIES

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any shares nor does it constitute financial product or investment advice nor take into account your investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this Presentation but must make its own assessment of the Company and conduct its own investigations and analysis. Before making an investment in the Company, a prospective investor should consider whether such an investment is appropriate to their particular investment objectives and financial situation and seek appropriate advice, including legal, taxation and financial advice appropriate to their jurisdiction and circumstances.

UNITED STATES


The Company's securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the **Securities Act**), or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the Company's securities may not be offered or sold, directly or indirectly, within the United States or to, or for the account of benefit of, U.S. Persons (as defined in Regulation S under the Securities Act as amended). This Presentation may not be distributed within the United States or to any person in the United States

OTHER JURISDICTIONS

This Presentation may only be accessed in other jurisdictions where it is legal to do so.


This Presentation is approved by the Board of Micro-X Limited

ersonal use only



CREATING REVOLUTIONARY X-RAY IMAGING TO BETTER LIVES

Curious | Collaborative | Determined



use only

ersons

OVERVIEW

Growing commercial momentum with Nano Electronic X-ray technology

MICRO-X

1

Delivered FY25 Total Revenue of \$13.1M - growing sales pipeline into FY26

2

Development work supported by partners – funding grew by \$36.6M in FY25¹

3

Refocused Rover Plus sales strategy building momentum - Major US healthcare operator win

4

Next NEX product has delivered the world's first 3D head CT images for stroke
– 3x human imaging hospital trials & ambulance fitment trials expected to commence in 2H 2025

5

New security partnerships to monetise technology - first partner in place
– \$5.6M with Billion Prima in Southeast Asia and negotiating with partners to take Checkpoints programme to market

1. \$12.5M contract with The Advanced Research Projects Agency for Health (ARPA-H) with \$12.5M option to extend. \$5.6M strategic partnership with Billion Prima for commercialisation of a baggage & parcel scanner
\$6.0M contract extension with the US department of Homeland Security

WORLD FIRST IMAGING TECHNOLOGY

Proprietary NEX Technology redefines portability and precision for X-ray innovation

MICRO-X



Micro-X imaging solution – X-ray Tubes – Generators – HV Connectors – Software

MEDICAL IMAGING PORTFOLIO

Pioneering smaller, smarter X-ray and CT through patented technology platform

MICRO-X


ROVER PLUS - MOBILE DIGITAL RADIOGRAPHY

Ultra-mobile x-ray systems delivering high quality images – hospital, remote, military




HEAD CT - MOBILE STROKE DIAGNOSIS

Light, portable CT imaging to diagnose strokes – air and road ambulances



FULL BODY CT - PORTABLE IMAGING SOLUTION


Light and portable CT imaging for all applications – portable use, rural and remote locations



Evolution of imaging products **enabled by advances in X-ray tubes**



2kg NEX DR tube



0.3kg NEX Mini tube

ersonal use only

VALIDATION & PARTNERS

Non dilutive funding to de-risk development and unlock value

MICRO-X

ersonal use only

Development Partners

Collaboration Partners



\$29m funding

Checkpoints & Baggage Scanner – U.S. Airports



\$25m funding

Full Body CT – Portable & Lightweight



Australian Stroke Alliance

\$8m funding

Head CT – Stroke Diagnosis

>\$80m
partnership funding



\$15m funding

Multibeam Emitters – Strategic investment



\$5.6m funding

Baggage & Parcel scanner – SE Asia



HARVARD UNIVERSITY



JOHNS HOPKINS UNIVERSITY



MONASH University

MICRO-X


RESULTS & HIGHLIGHTS

Financial Year ended 30 June 2025

KEY FINANCIALS – FY25

Growing commercial momentum driving tangible results


MICRO-X



Total Revenue¹

[FY24: \$15.2M]


Product sales declined with no Govt. orders.
Product sales offset by increased
partnership revenue in FY25



Project Revenue

[FY24 \$8.8M]

Revenue derived from milestones achieved
for Development Partners - ASA, DHS,
ARPA-H and Billion Prima



Operating EBITDA²

[FY24 -\$14.3M]

Managed cost base through a period
of declining revenues



1. Includes Project revenue of \$10.5M and Product revenue of \$2.6M

2. Operating EBITDA excludes the \$5.4M R&D Tax Rebate and other noncash charges including share-based payments and impairment related to Argus

OPERATIONAL ACHIEVEMENTS

New commercialisation strategy delivering results

MICRO-X



Major U.S. Supply Agreement

Supply Agreement with U.S. healthcare group – over 700 hospitals and healthcare facilities



\$25M to fund Full Body CT

ARPA-H funding to develop and deliver a Full Body CT using Micro-X's NEX technology



\$6.0M DHS Contract Ext.

Contract with U.S. Dept. of Homeland Security for Airport Checkpoint, funding up to \$29M

Further expansion into sports

Units in use in Major League Baseball, National Hockey League, College Basketball



World first 3D CT images

Test bench and software produces clinical quality images for skull phantom



\$5.6M Strategic Partnership

Strategic Partnership to develop and commercialise a Baggage & Parcel scanner

Varex transfer complete

Transfer of multi beam CNT technology to Varex completed - \$1.5M milestone payment



Gold award for Head CT

Head CT wins gold award at the Australian Good Design Awards



Checkpoint in lab testing

First fully functional prototype installed at U.S. Dept. of Homeland Security test laboratory

ersonal use only

REVENUE HIGHLIGHTS – FY25

Revenue driven by strong partnership activity – offsetting lumpy product income

\$2.6M Product Revenue



- Signed major US Supply Agreement in July 2025, expected to drive Rover Plus sales from FY26
- Elite sporting teams - US Baseball Teams
- Growing sales in Europe and Asia

\$10.5M Project Revenue

- DHS - \$4.6M for Checkpoint + Baggage Scanner
- ARPA-H - \$3.2M for Full Body CT project
- Billion Prima - \$1.9M for Baggage & Parcel scanner
- ASA - \$0.6M for Head CT milestones
- Other - \$0.2M

\$13.1M Total Revenue

- Transitioning the sales strategy towards high-quality, high-value opportunities versus smaller distributors
- Growth in fully funded development work on Project revenue streams offsets the impact from the short-term decrease in product revenue



PARTNERSHIP FUNDING – FY25


Reducing the cost base through partners funding product development

MICRO-X




Partnership Funding Secured

- Up to \$25M ARPA-H funding for the Full Body CT program
- \$6.0M Checkpoints contract extension from the DHS
- \$5.6M from Billion Prima for the Baggage & Parcel scanner



Partnership Funding Receipts

- 50% increase in partnership receipts over FY24 \$8.0M
- Milestones achieved for ASA, DHS, ARPA-H, Billion Prima and Varex



Unfunded Development Costs

- 46% reduction in unfunded development costs in FY25 (FY24: \$2.8M)
- In FY25 unfunded costs were for Argus which ceased in January 2025

BALANCE SHEET

All development workstreams fully funded by partnerships

MICRO-X

\$17.9M

Contracted payments for FY2026 onwards¹

→ Prioritising partnership funding to develop imaging portfolio and monetise security assets

- ASA funding covers Head CT development through till project completion
- Full Body CT work fully funded by ARPA-H for 2 years – second phase contingent on ARPA-H optional extension
- DHS and Billion Prima contracts underpin development for Checkpoints and Baggage scanners, contingent on milestones
- Rover Plus operations building towards being cashflow positive – key commercial goal in FY26 to grow sales
- Other payments and R&D rebate fund corporate overheads
- \$6.4M capital raised (before costs) in Q3 FY25

1. Future development contracts assuming all contract extension options are taken up by the DHS and ARPA-H

Balance Sheet

\$000

| | |
|------------------------------------|---------------|
| Cash & Cash Equivalents | 3,242 |
| Trade and Other Receivables | 8,321 |
| Inventories | 4,274 |
| Other Current Assets | 1,243 |
| Total Current Assets | 17,080 |
| Short-Term Debt – FY25 R&D rebate | 3,375 |

FY26 - Sources of Funding

\$000

| | |
|---|---------------|
| Sales of Micro-X Rover | In addition |
| Estimated R&D Rebate by 31 Dec 2025 | 5,400 |
| Contracted Project payments ^{2,3} | 12,200 |
| Sources of Funding – excluding Rover sales | 17,600 |

2. \$0.8m of this amount is included within 'Other Current Assets'

3. ARPA-H and DHS contracts subject to milestones - assuming both exercise optional funding


ersonal use only

MICRO-X

BUILDING COMMERCIAL TRACTION



Key building blocks are in place



STRATEGIES & PRIORITIES

MICRO-X

Three key near-term objectives focus to drive execution with a focus on tangible outcomes

01

Deliver large Rover Plus Sales

- Major healthcare group supply agreement

02

Commence Head CT imaging trials

- Pathway to regulatory application in 2026

03

Monetise Security Division

- Execute ongoing partnering negotiations

06

Build to Cashflow Breakeven

- Reducing unfunded costs with Contracts

05

Partnerships for commercial growth

- \$5.6m Billion Prima – Other partners underway

04

Focus on Medical Imaging

- Narrower focus to leverage core Micro-X technology

STRONG COMMERCIAL MOMENTUM

Commercial activity increasing for FY26

MICRO-X

1

Executing on Rover Plus sales opportunities

- Supply Contract in place with Major US Healthcare Group operates over 700 healthcare facilities
- Negotiations with major US Group Purchasing Organisation
- Ongoing major tenders in progress

2

Head CT advancing into clinical trials – 2027 planned launch

- Hospital and ambulance imaging trials to support regulatory approvals and launch in 2027
- Human imaging trials in three Australian hospitals planned for 2H 2025

3

Monetising security through Partnerships





- Billion Prima baggage scanner launched in late 2025 – will commence sales of Micro-X tubes and generators
- Partnering discussions are underway to secure partner to take baggage scanner and self-screening checkpoint to market – expected to release near term funding for Micro-X



COMMERCIAL TIMELINE


Commercialising a portfolio of products

MICRO-X


| Products | Funding / Status | 2025 | 2026 | 2027 |
|---|--|-------------------------------------|------------------------------|------------------------------|
|  | Approved / Revenue 400+ units sold to date | Execute larger sales opportunities | Cashflow positive operations | Further growth |
|  | 3D Images - Prototype \$8m ASA funding to prototype delivery | Human imaging trials - Hospital | Regulatory submission | Approval & Launch |
|  | Design stage Up to \$25m ARPA-H funding to prototype delivery | Phase 1 – Design & Prototype | | Phase 2 - Testing |
|  | Prototypes being tested Up to \$29m DHS contract to live testing | TSA testing - Algorithm enhancement | Deliver two more Checkpoints | Live testing in U.S. airport |


ersonal use only

CORPORATE & FINANCIALS



 **\$17.9M**
Contracted Payments FY26 onwards

 **\$13.1M**
FY25 Revenue

 **\$5.4M**
R&D Rebate estimate due Dec-25

FINANCIALS & SHAREHOLDERS

| | |
|------------------------------------|---|
| Cash | ~\$3.2M (30 June 2025) [\$1.9M received in July 25] |
| Revenue | \$13.1M (FY25) |
| Institutions & Strategic Investors | Perennial (12.9%), Acorn (10.7%), Varex (8.1%), Thorney (6.8%), Billion Prima (4.0%) |
| Board & Mgmt | 2.3% exc. Performance rights |

SHARE CAPITAL (26 August 2025)

| | |
|-----------------------|-------------------|
| Share price | \$0.079 per share |
| Total shares on issue | 667.2 million |
| Options (ex. 13.5c) | 31.1 million |
| Performance rights | 54.2 million |
| Convertible notes | 162.5k shares |
| Market cap | \$52.71 million |

EXPERIENCED LEADERSHIP

Commercially focused to accelerate growth

MICRO-X



Kingsley Hall – CEO

25+ years exp in senior operational and finance roles




Brian Gonzales, PhD – CEO Americas

Recognised industry leader in x-ray physics, CNT technology and x-ray imaging



Anthony Skeats – COO

25+ years exp R&D, Program and Engineering management in high technology products



Scott Bryant – CSO

Former US Navy veteran, with extensive experience in defense and robotics sales



Patrick O'Brien, Non-Exec Chair

Former Senior Exec. Macquarie Group, McKinsey and Minter Ellison



Jim McDowell, Non-Exec

Former Defence Deputy Sec, CEO Nova, CE SA Dept Premier & Cabinet



Ilona Meyer, Non-Exec

General Counsel Nuix, former Boehringer Ingelheim, ResMed, Medtronic



Andrew Hartmann, Non-Exec

Senior VP Varex Imaging, former Phillips, Carestream and Siemens

ersonal use only

ETHICAL & SUSTAINABLE CORPORATE GROWTH

Environmental, Social and Governance credentials

MICRO-X

ENVIRONMENT

ZERO

Environmental incidents

Development of 2026 Sustainability Strategy underway

Continuous waste reduction program

- Cost reductions in bottled gasses, nitrile gloves, wet chemicals and other high-usage consumables
- Focus on reduced waste to landfill and increased waste to recycling

PEOPLE

24%
Female employees



16 nationalities represented



25%
Female board

Veterans Employment Commitment



Diversity & Inclusion Policy in place



Autism SA Autism Friendly Charter



CSIRO STEM Professionals in Schools Program



Defence Industry Program Internships

ZERO

Fatalities or serious injuries since Micro-X founded

GOVERNANCE

US FDA, EU MDR, ARTG

ISO 13485, ISO 9001

Appointed new Company Secretary

Cybersecurity insurance policy in place

WRAP UP

A clear path forward

1

Commercial & customer focus is delivering results

2

Rover Plus sales momentum – building towards breakeven

3

Stroke imaging about to commence trials

4

Near term opportunity to monetise security business

5

Validated by strong partners – funding & access




ersonal use only

ersonal use only

MICRO-X

APPENDICES

F Y 2 5 F i n a n c i a l S t a t e m e n t s



PROFIT & LOSS – FY25

MICRO-X

Key Points

- Product Revenue decreased in FY25 with the focus on securing larger opportunities with longer sales cycles
- Project Revenue grew in line with strategy to develop technology through partners
- One off Impairment of \$1.9M for Argus IED x-ray camera inventory and demonstration equipment, discontinued from January 2025
- Total Expenses increased by \$1.6M (6.8%), largely attributable to Employee and Project development costs associated with an increase in contracted development work and associated Product Revenue
- Statutory NPAT loss of \$13.9M included \$5.1M non-cash expenses including depreciation & amortisation, impairment of assets and non-cash equity compensation.

| | Consolidated | | Change | |
|---|-----------------|-----------------|----------------|-------------|
| | 30-Jun-24 | 30-Jun-25 | \$'000 | % |
| | \$'000 | \$'000 | \$'000 | % |
| Revenues | | | | |
| Product Revenue | 6,410 | 2,590 | (3,820) | -60% |
| Costs of Goods sold | (5,403) | (2,426) | 2,977 | -55% |
| Project Revenue | 8,812 | 10,463 | 1,651 | 19% |
| Operating Revenues | 9,819 | 10,627 | 808 | 8% |
| Expenses | | | | |
| Employment expenses | 16,623 | 17,252 | 629 | 4% |
| Project development | 3,708 | 4,338 | 630 | 17% |
| Sales and Marketing | 937 | 910 | (27) | -3% |
| Corporate expenses | 430 | 328 | (102) | -24% |
| Other expenses | 2,465 | 2,975 | 510 | 21% |
| Total Expenses | 24,163 | 25,803 | 1,640 | 6.8% |
| Operating EBITDA | (14,344) | (15,176) | (832) | 5.8% |
| Non Operating Income & Costs | | | | |
| R&D Rebate | 6,373 | 5,430 | (943) | -15% |
| Grant income and Other | 367 | 161 | (206) | -56% |
| Depreciation & Amortisation | (1,539) | (1,570) | (31) | 2% |
| Finance expenses | (248) | (561) | (313) | 126% |
| Impairment of assets | (374) | (2,179) | (1,805) | 483% |
| Net Profit after Tax | (9,765) | (13,895) | (4,130) | 42% |

BALANCE SHEET – FY25

MICRO-X

Key points

- Cash & cash equivalents affected by timing – \$1.9M of receivables overdue were received in Jul 2025, providing a pro rata cash balance of \$5.1M
- Trade and Other Receivables includes an estimated \$5.4M R&D receivable relating to the FY25 year
- Borrowings increased to \$3.4M as a loan in relation to the 2025 R&D Tax Rebate expected to be repaid in Dec 25
- Reduction of \$1.1M of inventory due to the write down of Argus-related assets
- Property, Plant & Equipment decreased \$1M with the depreciation and impairment of Argus-related assets, marginally offset by additions

| | Consolidated | | Change | |
|---|---------------------|---------------------|----------------|-------------|
| | 30-Jun-24 \$'000 | 30-Jun-25 \$'000 | \$'000 | % |
| Assets | | | | |
| Current assets | | | | |
| Cash and cash equivalents | 3,228 | 3,242 | 14 | 0% |
| Trade and other receivables | 7,212 | 8,321 | 1,109 | 15% |
| Contract assets | 2,941 | 839 | (2,102) | -71% |
| Inventories | 5,379 | 4,274 | (1,105) | -21% |
| Other Assets | 1,138 | 404 | (734) | -64% |
| Total current assets | 19,898 | 17,080 | (2,818) | -14% |
| Non-current assets | | | | |
| Property, plant and equipment | 2,924 | 1,928 | (996) | -34% |
| Right-of-use assets and lease liabilities | 3,953 | 3,074 | (879) | -22% |
| Intangibles | 120 | 24 | (96) | -80% |
| Total non-current assets | 6,997 | 5,026 | (1,971) | -28% |
| Total assets | 26,895 | 22,106 | (4,789) | -18% |
| Liabilities | | | | |
| Current liabilities | | | | |
| Trade and other payables | 6,530 | 5,715 | (815) | -12% |
| Contract liabilities | 255 | 184 | (71) | -28% |
| Borrowings | | 3,375 | 3,375 | N/A |
| Lease liabilities | 692 | 659 | (33) | -5% |
| Provisions | 1,156 | 1,375 | 219 | 19% |
| Total current liabilities | 8,633 | 11,308 | 2,675 | 31% |
| Non-current liabilities | | | | |
| Lease liabilities | 3,298 | 2,499 | (799) | -24% |
| Provisions | 703 | 751 | 48 | 7% |
| Total non-current liabilities | 4,001 | 3,250 | (751) | -19% |
| Total liabilities | 12,634 | 14,558 | 1,924 | 15% |
| Net assets | 14,261 | 7,548 | (6,713) | -47% |
| Equity | | | | |
| Issued capital | 131,933 | 138,350 | 6,417 | 5% |
| Foreign currency translation reserve | 221 | 175 | (46) | -21% |
| Convertible notes | 65 | 65 | - | 0% |
| Share based payments reserve | 3,815 | 4,428 | 613 | 16% |
| Accumulated losses | (121,773) | (135,470) | (13,697) | 11% |
| Total equity | 14,261 | 7,548 | (6,713) | -47% |